Thus, there is considerable interest in developing molecules that can effectively antagonize mutant p53 amyloid aggregation and rescue the protein’s tumor suppressor function, leading to apoptosis in mutant p53-bearing cancer cells, while exhibiting negligible toxicity to noncancerous cells [220,221]. This evidence concerns the gene TP53 and cancer.